Document Detail

Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer.
MedLine Citation:
PMID:  18854619     Owner:  NLM     Status:  MEDLINE    
Radioiodine (I-131) therapy is of proven efficacy for treatment of differentiated thyroid carcinoma (DTC). However, loss of differentiation in recurrent or metastatic DTC which decrease I-131 uptake may decrease the efficacy of I-131 therapy. Therefore, strategies to improve I-131 uptake are mandatory. This study is an open label clinical study to evaluate the effectiveness of 13-cis retinoic acid (13-cis RA) for improving I-131 uptake in recurrent or metastatic of DTC with defective I-131 uptake. Eleven patients (Age 27-66 years, M : F=4 : 7) were given 13-cis RA (1.5 mg/kg daily for 5 weeks), followed by 200 mCi (7.4 GBq) I-131 treatment. The differences of serum thyroglobulin (Tg) level and I-131 uptake on the post-treatment whole body scan (RxWBS) were compared before and after 13-cis RA therapy. Six out of 11 patients showed significantly increased (above 50%) Tg levels just after RA therapy. However, Tg levels a year after I-131 therapy were increased, stable and decreased in 7, 2 and 1 patients, respectively. Iodine uptake on RxWBS showed marginal improvement in only 2 patients and their Tg levels after one year follow-up increased. Most frequent adverse events were dry skin and lips. 13-cis RA partially restores I-131 uptake in few patients with recurrent or metastatic DTC. The use of 13-cis RA in current protocol has only limited usefulness and is not routinely recommended as currently used protocol.
Won Gu Kim; Eui Young Kim; Tae Yong Kim; Jin-Sook Ryu; Suck Joon Hong; Won Bae Kim; Young Kee Shong
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-10-11
Journal Detail:
Title:  Endocrine journal     Volume:  56     ISSN:  1348-4540     ISO Abbreviation:  Endocr. J.     Publication Date:  2009  
Date Detail:
Created Date:  2009-03-13     Completed Date:  2009-04-21     Revised Date:  2011-06-16    
Medline Journal Info:
Nlm Unique ID:  9313485     Medline TA:  Endocr J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  105-12     Citation Subset:  IM    
Department of Endocrinology & Metabolism, University of Ulsan College of Medicine, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  pharmacology,  therapeutic use
Carcinoma, Papillary, Follicular / drug therapy*,  radiotherapy*
Cell Differentiation* / drug effects
Chemotherapy, Adjuvant / methods
Combined Modality Therapy
Iodine Radioisotopes / therapeutic use
Isotretinoin / adverse effects,  pharmacology,  therapeutic use*
Middle Aged
Radiotherapy Dosage
Thyroid Neoplasms / drug therapy*,  radiotherapy*
Treatment Failure
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 0/Iodine Radioisotopes; 4759-48-2/Isotretinoin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sig...
Next Document:  Barrett's esophagus and severe reflux esophagitis share common pathophysiological characteristics am...